Genetics and other technological advances are changing cancer diagnostics research, much as they have other areas of medicine, but researchers face, among other hurdles, information overload.
By Wendy Diller
Cancer diagnostics has been marked by grandiose hopes and numbing disappointments. Advances in our understanding of cancer haven't, to date,...
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Already a subscriber?
Banking on new billing codes for remote services, PAVmed’s Veris Health is expanding its oncology remote monitoring platform with Ohio State’s cancer center and developing an implantable physiological monitor to provide clinicians with continuous insights between treatment visits.
C-suite executives from Stryker, Intuitive Surgical and Fresenius passed a mainly upbeat verdict on the Indian medtech market and industry.
Abbott CEO Robert Ford said the diagnostics segment – pressured this year by China’s VBP and DRG reforms – is showing early signs of recovery, while the company’s operations in the US, Europe, and Latin America continue to grow at a healthy pace.
The $250m in new funding from HistoSonics’ new owners and new investors Thiel Bio and Founders Fund will expand its histotripsy platform globally, advance new indications, and scale operations. CEO Mike Blue tells Medtech Insight that an IPO isn’t an immediate priority.
The $250m in new funding from HistoSonics’ new owners and new investors Thiel Bio and Founders Fund will expand its histotripsy platform globally, advance new indications, and scale operations. CEO Mike Blue tells Medtech Insight that an IPO isn’t an immediate priority.
Evidence-based testing in real clinical settings and diagnostics tailored to community needs are crucial adoption success factors for new IVDs, Michael Wright, joint medical director at Newcastle Hospitals NHS Foundation Trust, told Medtech Insight at a regional UK meeting.
Armor Medical’s wrist-worn wearable detected postpartum hemorrhage five times earlier than standard care in earlier studies. After surviving near-fatal hemorrhage herself, co-founder/CEO Kelsey Mayo aims to bring the device to market in 2028.
